AU7051794A - Stable copper(1) complexes and methods related thereto - Google Patents

Stable copper(1) complexes and methods related thereto

Info

Publication number
AU7051794A
AU7051794A AU70517/94A AU7051794A AU7051794A AU 7051794 A AU7051794 A AU 7051794A AU 70517/94 A AU70517/94 A AU 70517/94A AU 7051794 A AU7051794 A AU 7051794A AU 7051794 A AU7051794 A AU 7051794A
Authority
AU
Australia
Prior art keywords
copper
complex
bcds
complexes
stable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU70517/94A
Other languages
English (en)
Inventor
Andrew Branca
Thomas M Marschner
Alexander J Pallenberg
Leonard M Patt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procyte Corp
Original Assignee
Procyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procyte Corp filed Critical Procyte Corp
Publication of AU7051794A publication Critical patent/AU7051794A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU70517/94A 1993-06-02 1994-06-02 Stable copper(1) complexes and methods related thereto Abandoned AU7051794A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7144093A 1993-06-02 1993-06-02
US071440 1993-06-02
PCT/US1994/006247 WO1994027594A2 (en) 1993-06-02 1994-06-02 Stable copper(i) complexes and methods related thereto

Publications (1)

Publication Number Publication Date
AU7051794A true AU7051794A (en) 1994-12-20

Family

ID=22101339

Family Applications (1)

Application Number Title Priority Date Filing Date
AU70517/94A Abandoned AU7051794A (en) 1993-06-02 1994-06-02 Stable copper(1) complexes and methods related thereto

Country Status (8)

Country Link
EP (1) EP0701439A1 (enrdf_load_stackoverflow)
JP (1) JPH08511006A (enrdf_load_stackoverflow)
AU (1) AU7051794A (enrdf_load_stackoverflow)
CA (1) CA2163640A1 (enrdf_load_stackoverflow)
OA (1) OA10198A (enrdf_load_stackoverflow)
TW (1) TW239077B (enrdf_load_stackoverflow)
WO (1) WO1994027594A2 (enrdf_load_stackoverflow)
ZA (1) ZA943857B (enrdf_load_stackoverflow)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562854B2 (en) 1994-12-14 2003-05-13 Axys Pharmaceuticals, Inc. Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders
AU6274896A (en) * 1995-06-06 1996-12-24 Procyte Corporation Stable copper(i) complexes as active therapeutic substances
US5637311A (en) * 1995-06-29 1997-06-10 Procyte Corporation Zinc(II) complexes and methods related thereto
US7045531B1 (en) 1997-03-11 2006-05-16 The General Hospital Corporation Composition comprising a metal chelator and a method of treating amyloidosis by administering the metal chelator
US6150379A (en) * 1997-11-26 2000-11-21 Axys Pharmaceuticals, Inc. Compounds and compositions as anticoagulants
US6638711B1 (en) 1999-04-29 2003-10-28 The General Hospital Corporation Methods for identifying an agent that inhibits oxygen-dependent hydrogen peroxide formation activity but does not inhibit superoxide-dependent hydrogen peroxide formation
WO2005115379A2 (en) * 2004-05-24 2005-12-08 New York University Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
NZ565003A (en) * 2005-06-20 2011-11-25 Dynamiclear Pty Ltd Composition for treating skin lesions
KR20110054035A (ko) * 2008-09-03 2011-05-24 가부시키가이샤 엔비씨 메슈테크 항바이러스제
US10098857B2 (en) 2008-10-10 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds
TWI580787B (zh) * 2012-12-28 2017-05-01 簡宏堅 重組蛋白質、含有該重組蛋白質之醫藥組成物及該重組蛋白質之製備方法
US11331288B2 (en) 2017-09-14 2022-05-17 The Board Of Trustees Of The Leland Stanford Junior University Conditioning irradiated tissue for increasing vascularity
CA3102395A1 (en) * 2018-06-04 2019-12-12 Chemistryrx. Topical compositions for stimulating hair growth

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4760051A (en) * 1985-01-24 1988-07-26 Pickart Loren R Use of GHL-Cu as a wound-healing and anti-inflammatory agent
JPS6259213A (ja) * 1985-09-10 1987-03-14 Eisai Co Ltd ス−パ−オキサイド除去剤

Also Published As

Publication number Publication date
OA10198A (en) 1996-12-18
ZA943857B (en) 1995-02-01
WO1994027594A3 (en) 1995-04-27
CA2163640A1 (en) 1994-12-08
EP0701439A1 (en) 1996-03-20
TW239077B (enrdf_load_stackoverflow) 1995-01-21
JPH08511006A (ja) 1996-11-19
WO1994027594A2 (en) 1994-12-08

Similar Documents

Publication Publication Date Title
Kimura et al. Increases in cyclic GMP levels in brain and liver with sodium azide an activator of guanylate cyclase
EP1088098B2 (en) Fitness assay and methods for reducing resistance of hiv to therapy
Lugnier et al. Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta
AU7051794A (en) Stable copper(1) complexes and methods related thereto
US5457130A (en) Eicosapentaenoic acid used to treat cachexia
Schröder et al. Modulation of nuclear matrix-associated 2′, 5′-oligoadenylate metabolism and ribonuclease L activity in H9 cells by human immunodeficiency virus
JP2009242438A (ja) ノルジヒドログアヤレティク酸誘導体を使用して腫瘍を処置するための方法
WO1996039144A1 (en) Stable copper(i) complexes as active therapeutic substances
Hall et al. Anti-inflammatory agents III: Structure–activity relationships of brusatol and related quassinoids
CA2042569A1 (en) Stabilized fgf composition
WO2001037819A2 (fr) Utilisation de derives d'indirubine pour la fabrication de medicaments
Sharkey et al. Pharmacokinetics and antitumor properties in tumor-bearing mice of an enediol analogue inhibitor of glyoxalase I
US5637311A (en) Zinc(II) complexes and methods related thereto
Diebold et al. Influences of lovastatin administration on the respiratory burst of leukocytes and the phosphorylation potential of mitochondria in guinea pigs
Wick et al. Inhibition of reverse transcriptase by tyrosinase generated quinones related to levodopa and dopamine
EP0774252A1 (en) Cytokine potentiator and remedy for diseases wherein cytokine activity is reduced
Hostetler et al. Lipid prodrugs of phosphonoacids: greatly enhanced antiviral activity of 1-O-octadecyl-sn-glycero-3-phosphonoformate in HIV-1, HSV-1 and HCMV-infected cells, in vitro
Van Gelder et al. Inhibition of intestinal metabolism of the antiviral ester prodrug bis (POC)-PMPA by nature-identical fruit extracts as a strategy to enhance its oral absorption: an in vitro study
Baker et al. Synthesis and evaluation of a series of 2'-O-acyl derivatives of 9-. beta.-D-arabinofuranosyladenine as antiherpes agents
EP0316117A1 (en) Antiviral compounds, compositions containing such compounds and methods of treatment
Miyagi et al. Multiple forms of mammalian sialidase: altered expression in carcinogenesis
Eames et al. Orientation, accessibility, and mobility of equilenin bound to the active site of steroid isomerase
Satoh et al. Inhibition of Na+, K+-ATPase by the extract of Stephania cephararantha Hayata and bisbenzylisoquinoline alkaloid cycleanine, a major constituent
WicK et al. Antitumor effects of L-glutamic acid dihydroxyanilides against experimental melanoma
ADACHI et al. The effects of 1, 2, 3, 4, 6-penta-O-galloyl-β-D-glucose on rat liver mitochondrial respiration